Cardiometabolic Disease
Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants
Scientific Publications & Presentations
Built on decades of scientific leadership, Ionis continues to advance the understanding of disease through groundbreaking research and innovation. Explore select publications across our therapeutic areas and technologies to better understand the science behind our medicines and pipeline.
Showing 25-36 out of 51 results
Neurology
Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series
Cardiometabolic Disease
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)
Cardiometabolic Disease
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America
Neurology
ION582 Data Presented at the Angelman Syndrome Foundation Family Conference and Research Symposium
Cardiometabolic Disease
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Cardiometabolic Disease
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Cardiometabolic Disease
Olezarsen Data Presented at the 2024 American College of Cardiology Annual Meeting
Neurology
Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease A Randomized Clinical
Neurology
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Neurology
Eplontersen Data Presented at the American Academy of Neurology Annual Meeting
Neurology
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial